AbbVie Inc. (ABBV)

US — Healthcare Sector
Peers: MRK  PFE  LLY  BMY  JNJ  AMGN  GILD 

Automate Your Wheel Strategy on ABBV

With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ABBV
  • Rev/Share 32.9165
  • Book/Share -0.0779
  • PB -2242.0157
  • Debt/Equity -385.1421
  • CurrentRatio 0.7358
  • ROIC 0.1416

 

  • MktCap 409028897900.0
  • FreeCF/Share 10.2929
  • PFCF 22.4261
  • PE 108.8588
  • Debt/Assets 0.5138
  • DivYield 0.0279
  • ROE 1.4231

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade ABBV Berenberg Hold Buy -- $270 Sept. 17, 2025
Resumed ABBV Piper Sandler -- Overweight -- $231 Aug. 12, 2025
Upgrade ABBV Daiwa Securities Neutral Outperform -- $214 Aug. 7, 2025
Downgrade ABBV Citigroup Buy Neutral -- $205 May 14, 2025
Initiation ABBV Cantor Fitzgerald -- Overweight -- $210 April 22, 2025
Resumed ABBV BofA Securities -- Neutral -- $191 Dec. 10, 2024
Downgrade ABBV Daiwa Securities Outperform Neutral -- $180 Dec. 5, 2024
Initiation ABBV Bernstein -- Market Perform -- $203 Oct. 17, 2024

News

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
ABBV
Published: September 30, 2025 by: PRNewsWire
Sentiment: Neutral

Expansion increases biologics manufacturing for immunology and oncology medicines Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing Furthers longstanding commitment to AbbVie's Massachusetts sites and workforce NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass.

Read More
image for news AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
ABBV
Published: September 30, 2025 by: PRNewsWire
Sentiment: Neutral

– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of investigational Pivekimab sunirine (PVEK) for treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Read More
image for news AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
ABBV, SOLTF
Published: September 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.

Read More
image for news Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.

Read More
image for news AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
ABBV
Published: September 29, 2025 by: PRNewsWire
Sentiment: Neutral

New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by 2027 Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing NORTH CHICAGO, Ill. , Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois.

Read More
image for news AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
ABBV
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie to launch ovarian cancer drug in UK at the same list price as US
ABBV
Published: September 29, 2025 by: Reuters
Sentiment: Positive

AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.

Read More
image for news AbbVie to launch ovarian cancer drug in UK at the same list price as US
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
ABBV
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.

Read More
image for news Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
ABBV
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape.

Read More
image for news AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
ABBV
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.

Read More
image for news Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
ABBV
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Neutral

ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.

Read More
image for news AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
AbbVie shares rise with extension of RINVOQ patent protection to 2037
ABBV
Published: September 11, 2025 by: Proactive Investors
Sentiment: Positive

Abbvie Inc (NYSE:ABBV) shares moved higher after the pharma company announced it has secured extended patent protection for its blockbuster autoimmune drug RINVOQ (upadacitinib). It said in a regulatory filing that it has reached settlements with all generic manufacturers that had filed applications to produce generic versions of RINVOQ, effectively extending US patent protection until April 2037, assuming pediatric exclusivity is granted.

Read More
image for news AbbVie shares rise with extension of RINVOQ patent protection to 2037
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
ABBV
Published: September 11, 2025 by: Reuters
Sentiment: Positive

AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, according to some analysts.

Read More
image for news AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
AbbVie in Settlement With Generic Drugmakers on Rinvoq
ABBV
Published: September 11, 2025 by: WSJ
Sentiment: Positive

The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.

Read More
image for news AbbVie in Settlement With Generic Drugmakers on Rinvoq
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
ABBV
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Read More
image for news AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie: What's Happening With ABBV Stock?
ABBV
Published: September 11, 2025 by: Forbes
Sentiment: Positive

AbbVie's stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq, until 2037.

Read More
image for news AbbVie: What's Happening With ABBV Stock?
AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
ABBV
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral

AbbVie Inc. (NYSE:ABBV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.

Read More
image for news AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Calls of the Day: Abbvie, Vertex, Veeva and Vistra
ABBV, VEEV
Published: September 08, 2025 by: CNBC Television
Sentiment: Neutral

The Investment Committee discuss the latest Calls of the Day.

Read More
image for news Calls of the Day: Abbvie, Vertex, Veeva and Vistra
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
ABBV, JNJ
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.

Read More
image for news J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
AbbVie Declares Quarterly Dividend
ABBV
Published: September 05, 2025 by: PRNewsWire
Sentiment: Neutral

NORTH CHICAGO, Ill. , Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.

Read More
image for news AbbVie Declares Quarterly Dividend
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
ABBV
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.

Read More
image for news Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
Investing in the Age of Longevity: Silver Economy Stocks in Focus
ABBV, AMGN, DXCM, SYK
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.

Read More
image for news Investing in the Age of Longevity: Silver Economy Stocks in Focus
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
ABBV, MRK
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.

Read More
image for news ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
ABBV
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Best Dividend Aristocrats For September 2025
ABBV, ABT, ADM, ADP, AFL, ALB, AMCR, AOS, APD, ATO, BDX, BEN, BRO, CAH, CAT, CB, CHD, CHRW, CINF, CL, CLX, CTAS, CVX, DOV, ECL
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, has outperformed both NOBL and SPY in August.

Read More
image for news Best Dividend Aristocrats For September 2025
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
ABBV
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.

Read More
image for news What Is the Intent Behind AbbVie's Recent Acquisition Spree?
AbbVie: Plenty Of Positives
ABBV
Published: August 26, 2025 by: Seeking Alpha
Sentiment: Positive

AbbVie has had a good August, with double digit MoM gains after seeing weakness for six months. Factors like an EU-US deal on pharmaceuticals, recent results, improved guidance, positive outcomes in using Rinvoq to treat alopecia and even the expansion of its neuroscience portfolio support ABBV. However, the recent acquisition of a depression treatment candidate can impact the earnings outlook at a time when its market multiples already look stretched.

Read More
image for news AbbVie: Plenty Of Positives
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
ABBV
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Neutral

AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter's lead pipeline candidate, bretisilocin (GM-2505), a novel therapy being developed for treating major depressive disorder(MDD).

Read More
image for news ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
AbbVie Is A Top Biotech Pick
ABBV
Published: August 25, 2025 by: Seeking Alpha
Sentiment: Positive

Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies. The company's Rinvoq drug has new market potential and U.S. manufacturing plans are likely to help mitigate tariff headwinds successfully. EPS guidance for the full year was raised and consensus estimates also show that the outlook for AbbVie is a strong one.

Read More
image for news AbbVie Is A Top Biotech Pick
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion
ABBV
Published: August 25, 2025 by: Reuters
Sentiment: Positive

AbbVie said on Monday it would buy privately held Gilgamesh Pharmaceuticals' treatment for major depressive disorder in a deal worth up to $1.2 billion.

Read More
image for news AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion

About AbbVie Inc. (ABBV)

  • IPO Date 2013-01-02
  • Website https://www.abbvie.com
  • Industry Drug Manufacturers - General
  • CEO Robert A. Michael CPA
  • Employees 55000

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.